Quotables
"Rail travel at high speeds is not possible because passengers, unable to breathe, would die of asphyxia."
Dionysius Lardner, Professor of Natural Philosophy and Astronomy at University College, London ; 1830
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8187587 | Immunotherapeutic methods targeted toward stratum corneum chymotryptic enzyme The present invention discloses the protease stratum corneum chymotrytic enzyme (SCCE) is specifically over-expressed in ovarian and other malignancies. A number of SCCE peptides can induce immune responses to SCCE, thereby demonstrating the potential of these pepti... | 05/29/2012 |
| 8168169 | Methods and compositions for the treatment of medical disorders In general, the invention relates to marrow-derived adult progenitor cells (MAPCs) and their use in methods of treating various medical disorders, typically caused by or involving loss of cells or loss of cell function. These cells, when administered, e.g., intranas... | 05/01/2012 |
| 8153117 | Chondrocyte therapeutic delivery system Methods and compositions for producing therapeutic agents using chondrocytes are provided. The genetically engineered chondrocytes can be used to express the therapeutic agent in a subject, including in an environment typically associated with chondrocytes and in an... | 04/10/2012 |
| 8142771 | Use of coccidian The present invention provides a novel use of coccidian, specifically relates to the use of coccidian as a vaccine live vector. The present invention further provides a live vaccine with coccidian as a vector, which is transgenic coccidian capable of expressing exog... | 03/27/2012 |
| 8142772 | Attack of tumor cells with missing, low or aberrant MHC expression by combining non MHC-restricted T-cells/NK-cells and MHC-restricted cells This invention is directed to therapeutic compositions containing non-MHC-restricted Tcells/NK-cells in combination with MHC-restricted T-cells and especially to therapeutic compositions, which comprise LAK cells. Furthermore, the present invention is directed to th... | 03/27/2012 |
| 8128922 | Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen Nucleic acids encoding a chimeric or fusion polypeptide which polypeptide comprises a first domain comprising a translocation polypeptide; and a second domain comprising at least one antigenic peptide are disclosed. The preferred translocation polypeptide is a bacte... | 03/06/2012 |
| 8124069 | Immunogenic peptides The invention provides relatively short immunogenic peptides, and biologically active variants thereof, associated with leukemia which elicit an immune response. Nucleic acids encoding the immunogenic peptides and antibodies specific for the peptides are also provid... | 02/28/2012 |
| 8106010 | Variants of pigment epithelium derived factor and uses thereof The present invention relates to anti-angiogenic variants of pigment epithelium derived factor (PEDF) comprising a plurality of altered phosphorylation sites, polynucleotides encoding same and uses thereof. In particular, the PEDF variants of the present invention p... | 01/31/2012 |
| 8097243 | Microparticle-based transfection and activation of dendritic cells The present invention provides an effective method for the transfection of dendritic cells by non-viral methods. The present invention provides this benefit by incubating dendritic cells and a specified transfection agent. The transfection agent comprises a polynucl... | 01/17/2012 |
| 8092792 | Use of materials for treatment of central nervous system lesions Disclosed are methods and materials for treatment of central nervous system lesions. Preferred methods and materials comprise neuronal precursor cells and/or marrow adherent stem cell-derived neuronal cells. ... | 01/10/2012 |
| 8071085 | Primary cultured adipocytes for gene therapy The present invention relates to primary cultured adipocytes for gene therapy, where the adipocytes stably maintain a foreign gene encoding a protein that is secreted outside of cells. This invention provides cells suitable for gene therapy, which can replace bone m... | 12/06/2011 |
| 8066985 | Reovirus for the treatment of cellular proliferative disorders Methods for treating proliferative disorders, by administering reovirus to a Ras-mediated proliferative disorder, are disclosed. The reovirus is administered so that it ultimately directly contacts ras-mediated proliferating cells. Proliferative disorders include bu... | 11/29/2011 |
| 8066984 | Modified vaccinia virus strains for use in diagnostic and therapeutic methods Modified viruses and methods for preparing the modified viruses are provided. Vaccines that contain the viruses are provided. The viruses can be used in methods of treatment of diseases, such as proliferative and inflammatory disorders, including cancer, and as anti... | 11/29/2011 |
| 8052968 | Modified vaccinia virus strains for use in diagnostic and therapeutic methods Modified viruses and methods for preparing the modified viruses are provided. Vaccines that contain the viruses are provided. The viruses can be used in methods of treatment of diseases, such as proliferative and inflammatory disorders, including as anti-tumor agent... | 11/08/2011 |
| 8034332 | Interleukin-secreting natural killer cell lines and methods of use This invention relates to a natural killer cell line termed NK-92 and to NK-92 cell lines that have been modified by transfection with a vector to confer advantageous properties. The invention provides a modified NK-92 cell line that is transfected with a vector enc... | 10/11/2011 |
| 8012469 | Universal GM-CSF expressing bystander human K562 cell line The present invention provides a universal immunomodulatory cytokine-expressing bystander cell line, a composition comprising such a cell line and a cancer antigen, a method of making such a cell line, and a method of using such a composition. ... | 09/06/2011 |
| 8012468 | Dendrite cells transduced with recombinant adenovirus AdVCEA which generate CEA-specific cytotoxic T lymphocytes, vaccine and pharmaceutical composition comprising the same The present invention relates to an antitumor immune response, and in more detail, to a method for inducing cytotoxic T lymphocytes specific to a tumor-associated antigen that acts specifically on tumor cells. Immunotherapy using the present invention may be ... | 09/06/2011 |
| 8007781 | Molecular vaccine linking an endoplasmic reticulum chaperone polypeptide to an antigen This invention provides compositions and methods for inducing and enhancing immune responses, such as antigen-specific cytotoxic T lymphocyte (CTL) responses, using chimeric molecules comprising endoplasmic reticulum chaperone polypeptides and antigenic peptides. In... | 08/30/2011 |
| 7988959 | Method of treatment using organotypically cultured skin tissue comprising niks cells that express exogenous HIF-1a The present invention relates to in vitro cultured skin tissue, and in particular to cultured skin tissue comprising exogenous genes encoding angiogenic growth factors. In some embodiments, the keratinocytes express exogenous angiopoietin-1, HIF-1α, or a member of ... | 08/02/2011 |
| 7989427 | Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapy A novel nucleic acid construct for down-regulating angiogenesis in a tissue of a subject is provided. The nucleic acid construct includes: (a) a first polynucleotide region encoding a chimeric polypeptide including a ligand binding domain fused to an effector domain... | 08/02/2011 |
| 7968087 | Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells A gene delivery vehicle having been provided with at least a tissue tropism for cells selected from the group of smooth muscle cells, endothelial cells, and/or liver cells. The tissue tropism is generally provided by a virus capsid, such as one comprising protein fr... | 06/28/2011 |
| 7939059 | Method for the generation of antigen-specific lymphocytes The invention provides systems and methods for the generation of lymphocytes having a unique antigen specificity. In a preferred embodiment, the invention provides methods of virally infecting cells from bone marrow with one or more viral vectors that encode antigen... | 05/10/2011 |
| 7919475 | Compositions and methods for improving heart function The present invention relates to treating or ameliorating heart disease associated with poor myocardial performance, e.g., diabetic cardiomyopathy and associated disorders, particularly to treating, preventing or ameliorating such disorders through inhibition of O-G... | 04/05/2011 |
| 7919079 | Cancer immunotherapy compositions and methods of use Cellular compositions and methods for inducing an immune response to tumor cells are described. The cellular compositions include a tumor antigen and cells that have been modified to express a cytokine and one or more of a tumor antigen, anti-CTLA4 antibody and an a... | 04/05/2011 |
| 7919080 | Immortalized hepatocyte cell line secreting modified insulin with glucose sensitivity The present invention provides a cell line which can be substituted for β cells in human mature pancreatic islets and express insulin in a glucose-concentration dependent manner, and enables the easy obtainment of the number of cells which meets the demand. The pre... | 04/05/2011 |
| 7892532 | Intracellular delivery of osteoinductive proteins and peptides The invention provides fusion polypeptides comprising protein transduction domains and osteoinductive polypeptides, as well as methods of using such polypeptides to induce osteogenesis and to promote proteoglycan synthesis. The invention also provides osteoinductive... | 02/22/2011 |
| 7893033 | Targeting proteins to deliver therapeutic or diagnostic reagents The present invention is directed to compositions comprising an angiogenesis inhibitor coupled to a therapeutic or diagnostic agent. In a specific embodiment, the composition is a fusion gene or fusion gene product encoding the angiogenesis inhibitor coupled to a th... | 02/22/2011 |
| 7887793 | Treatment of Duchenne muscular dystrophy with myoblasts expressing dystrophin and treated to block myostatin signaling The invention relates to methods and materials for enhancing muscle mass or for the treatment of muscle disease in a subject, comprising introducing a cell which has a lower than normal level of myostatin signalling, into the subject. ... | 02/15/2011 |
| 7875274 | Protein modulators of resistance to alkylating agents There is disclosed a method for identifying a therapeutically responsive phenotype, as distinguished, e.g. from an alkylating agent resistant phenotype in a cell, which method may be used to evaluate the likelihood of successful outcome of treating a tumor cell with... | 01/25/2011 |
| 7850960 | Methods for regulation of stem cells Methods are provided for increasing stem cells, hematopoietic progenitor/stem cells, mesenchymal progenitor/stem cells, mesodermal progenitor/stem cells, muscle progenitor/stem cells, or neural progenitor/stem cells in vivo in a mammalian subject. Methods are also p... | 12/14/2010 |
| 7850959 | Methods and compositions for treating conditions involving abnormal angiogenesis The present invention features methods and compositions for preventing, reducing, or treating hypoxia and pathological disorders involving abnormal angiogenesis (e.g., conditions involving decreases or increases in blood flow, respectively). Where an increase in ang... | 12/14/2010 |
| 7846429 | Compositions and methods for elimination of unwanted cells Disclosed are compositions comprising a recombinant nucleic acid vector including a nucleotide sequence encoding a syncytium-inducing polypeptide expressible on a eukaryotic cell surface, and a host cell containing the recombinant vector and expressing the syncytium... | 12/07/2010 |
| 7807148 | Organotypically cultured skin tissue comprising NIKS cells that express exogenous HIF-1a The present invention relates to in vitro cultured skin tissue, and in particular to cultured skin tissue comprising exogenous genes encoding angiogenic growth factors. In some embodiments, the keratinocytes express exogenous angiopoietin-1, HIF-1α, or a member of ... | 10/05/2010 |
| 7799324 | Using undifferentiated embryonic stem cells to control the immune system This disclosure provides a system for minimizing the alloreactivity of tissue transplants. The patient is administered with undifferentiated embryonic stem cells or early progenitor cells. This induces a state of inflammatory quiescence or immune unresponsiveness, w... | 09/21/2010 |
| 7794702 | Mesenchymal stem cells as a vehicle for ion channel transfer in syncytial structures This invention provides a composition for delivery of a gene to a syncytial structure comprising stem cells incorporated with the gene. This invention also provides a composition for ion channel transfer which comprises stem cells incorporated with a compound in an ... | 09/14/2010 |
| 7794703 | Method for production and delivery of a protein in vivo A method for production and delivery of a protein in vivo is described. The method includes steps of inserting a promoter and a gene encoding a protein in a vector, collecting an amount of host cells from a mammal, treating the host cells in vitro with the vector, t... | 09/14/2010 |
| 7767201 | Vascular cells genetically altered to over-express angiogenic proliferation and maturation factors; treatment of atherosclerosis using same This invention relates to a method for producing angiogenesis in a tissue of a patient by administering vascular cells genetically altered to over-express an angiogenic proliferation factor and an angiogenic maturation factor to the affected tissue. ... | 08/03/2010 |
| 7767202 | Modulation of systemic immune responses by transplantation of hematopoietic stem cells transduced with genes encoding antigens and antigen presenting cell regulatory molecules The invention provides methods and compositions for the modulation of systemic immune responses by transplantation of hematopoietic stem cells transduced with genes encoding antigens and antigen presenting cell regulatory molecules. The invention includes bi-cistron... | 08/03/2010 |
| 7754202 | Methods of controlling cell differentiation and growth using a fusion protein and a drug This invention involves methods and materials for conferring a direct proliferative advantage on a genetically modified subpopulation of cells. Selection is then accomplished by exerting a positive selective stimulus on the engineered cells rather than a negative pr... | 07/13/2010 |
| 7740837 | Genetically modified cells expressing a TGF beta inhibitor, the cells being lung cancer cells The present invention relates to compositions comprising a therapeutically effective amount of genetically modified cells containing a genetic construct expressing a TGFβ inhibitor effective to reduce expression of TGFβ, where the genetically modified cells are no... | 06/22/2010 |
